Legislators Urge HASC to OK Psychedelic Research Targeting PTSD Treatment

A surge in psychedelic research in recent years has revealed something quite interesting: several psychedelic drugs are capable of alleviating symptoms of mental disorders with relatively few side effects. Dubbed the psychedelic renaissance, this movement has seen dozens of researchers across the world focus their attention on determining the possible benefits of leveraging psychedelic therapies in mental health treatment.

Given that a large portion of the American population battles with mental illness every day and existing treatments aren’t always effective, safe and efficient psychedelic-assisted therapies will likely aid millions of people in their situations. One of the areas of research that scientists have focused on is the therapeutic potential of psychedelics against mental disorders such as post-traumatic stress disorder (PTSD), which often have poor treatment outcomes and significantly disrupt patients’ lives.

Legislators are now asking the House Armed Services Committee (HASC) to okay the research of psychedelic drugs to treat PTSD in army veterans. PTSD is a debilitating mental disorder that is often characterized by extreme anxiety, nightmares, hypervigilance, poor sleep, irritability and flashbacks to traumatic events.

Due to their higher-than-average exposure to very high-pressure situations and traumatic experiences on the battlefield, soldiers are significantly more likely to develop PTSD in their lifetimes.

Representative Dan Crenshaw, a Navy SEAL veteran, told the committee that congressional lawmakers should approve grants to research the potential of using psychedelics to treat traumatic brain injury and PTSD. He urged the committee to “think outside the box,” especially regarding psychedelics such as MDMA, when it comes to treating army vets with brain injuries. Crenshaw also stated the we have a long way to go in regard to treating PTSD and the effects of traumatic brain injury.

Research into the therapeutic potential of psychedelics against PTSD would be simple and would allow clinicians to make a positive step toward alleviating brain-related trauma.

Although the military hasn’t invested significantly in psychedelic research, other studies have indicated that hallucinogenic drugs such as MDMA (ecstasy) have the potential to deliver long-term relief for patients with PTSD.

Crenshaw, who served several tours in Afghanistan and Iraq, said the stories of veterans who benefited from psychedelic therapy are more compelling than the data collected in studies. He noted that the treatment these veterans to shed their suicidal thoughts, “rescue their marriages” and get their lives on track. Furthermore, Crenshaw noted that psychedelic therapy had also helped some veterans stop abusing alcohol and other drugs.

Many for-profit entities such as Compass Pathways PLC (NASDAQ: CMPS) are conducting studies aimed at commercializing various psychedelic treatments for mental health conditions. The results of these studies could give military veterans additional options to consider when they are diagnosed with PTSD or other psychiatric conditions.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.